Brussels, July 4, 2024 – Syensqo and Allozymes, a Singaporean enzyme engineering start-up, announce the signing of a Memorandum of Understanding (MOU) to leverage their strengths in biotechnology towards the development of advanced biosolutions for home and personal care, particularly in the skincare market.
Allozymes stands out in the bio-engineering sector with its unique ultra-high throughput microfluidics platform for the engineering of enzymes and microbes. This platform enables the rapid and cost-effective development of biomanufactured ingredients and bioprocesses, setting a new standard for innovation and sustainability in the industry.
“By combining Allozymes’ technological capabilities with Syensqo’s application and market access expertise, we are poised to create groundbreaking solutions that will not only benefit the home and personal care market but also contribute to a more sustainable future,” said Thomas Canova, head of Renewable Materials & Biotechnology growth platform at Syensqo.
This MOU marks an important milestone in Syensqo’s strategic agenda of rapidly expanding its beauty specialty ingredients portfolio based on biotechnology. It complements the company’s recent acquisition of South Korean ceramides specialist JinYoung Bio, further solidifying its commitment to enabling sustainable and innovative care solutions.
“Our partnership with Syensqo embodies our mutual commitment to a sustainable future, leveraging biotechnology to enable cleaner, greener processes, ensuring our actions today contribute to a healthier planet for future generations. Together, we’re setting a new standard for environmental stewardship,” added Peyman Salehian, PhD, CEO and cofounder at Allozymes.
